ArticleBMC psychiatry2013
Levels of S100B are raised in female patients with schizophrenia.
Article in BMC psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.PloS one · 2014Pooled it
- Gender differences in plasma S100B levels of patients with major depressive disorder.BMC psychiatry · 2024Article
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Vascular-related biomarkers in psychosis: a systematic review and meta-analysis.Frontiers in psychiatry · 2023Review
- Systematic Review and Meta-Analysis of Damage Associated Molecular Patterns HMGB1 and S100B in Schizophrenia.Psychiatry investigation · 2022Article
- Schizophrenia and Alarmins.Medicina (Kaunas, Lithuania) · 2022Review
- Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders.Current neuropharmacology · 2021Review
- Racial Differences in S100b Levels in Persons with Schizophrenia.The Psychiatric quarterly · 2020Article
- Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.Schizophrenia research · 2016Review
- Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.Scientific reports · 2016Article
- Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia-A Meta-Regression Analysis.Frontiers in cellular neuroscience · 2016Article
- Inflammation and Elevation of Interleukin-12p40 in Patients with Schizophrenia.Frontiers in molecular neuroscience · 2016Article
- Regulation of S100B in white adipose tissue by obesity in mice.Adipocyte · 2014Article
- The Serum S100B Level as a Biomarker of Enteroglial Activation in Patients with Ulcerative Colitis.International journal of inflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe neurotrophic factor, S100B, is released primarily from astrocytes, with serum and CSF levels of S100B reported as altered in schizophrenia. However, many of these reports are contradictory. Here, serum levels of S100B in schizophrenia and influence of age, gender, medication and illness severity were examined.
methodsSerum S100B levels were measured in patients with schizophrenia treated with clozapine. Lifestyle, metabolic and illness severity parameters were correlated with S100B concentrations.
resultsData showed raised serum levels of S100B in schizophrenia female patients, but not male patients, compared to controls. Correlation analysis demonstrated a positive association between S100B serum concentrations and BMI.
conclusionsThis study supports previous findings that adipocytes may contribute to S100B serum concentrations in females, in addition to astrocytes. This study also supports the hypothesis that metabolic effects of medication, lifestyle choices and the illness itself, may be contributing factors to altered levels of S100B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.